Product Images Losartan Potassium

This is a drug package insert for Losartan Potassium tablets, containing 100mg of Losartan. The tablets are film-coated and are used according to the dosage specified in the package insert. The tablets are manufactured by Micro Labs Limited in Goa, India and are distributed in the USA by Micro Labs USA, Inc. The tablets should be stored at room temperature between 15°C to 30°C and protected from light. The package contains a patient information leaflet.*

Each film-coated tablet contains Losartan Potassium, USP 25 mg. The tablets should be stored at 25°C (77°F) with permitted excursions to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. The container should be kept tightly closed and protected from light. The usual dosage should be seen on the package insert. The tablets are manufactured by Micro Labs Limited in Goa-403 722, India and a patient information leaflet is attached. The product is manufactured for Micro Labs USA, Inc. and comes in a pack of 30 tablets.*

This is a medication description for Losartan Potassium tablets with a strength of 50mg per tablet. The usual dosage is not specified and should be referred to in the package insert. The tablets should be stored at a temperature of 25°C and can be kept for excursions to 15°-30°C. The container needs to be tightly closed and kept away from light. The medication is manufactured by Micro Labs Limited, located in Goa, India, for Micro Labs USA, Inc. This text includes an NDC number, and the instructions are primarily directed towards pharmacists.*

This seems to be a chart or table from a study that compares the effectiveness of Atenolol and Losartan Potassium in reducing a primary endpoint. It shows the adjusted risk reduction of 13% for Losartan Potassium with a p-value of 0.021. The table shows the study duration in the form of months for up to 66 months.*

This is a chart that shows the percentage of patients who had a fatal or non-fatal stroke. The chart compares the drug Atenolol to the drug Osartan Potassium. The adjusted risk reduction for Osartan Potassium is 25%, with a p-value of 0.001. The x-axis shows the study months from 0 to 60.*

This data display shows a graph that indicates the percentage of patients who experienced an event, with the x-axis being the number of patients, and y-axis indicating the percentage of patients. The number "60" at the top of the graph is ambiguous, and the numbers "40" and "20" on the y-axis refer to percentages. The text below the graph indicates a risk reduction percentage of 16.1% and a p-value of 0.022.*